Physician profile
Michael Jacobson
NPI 1649352964
$7,041.86
in general payments reported to CMS, 2019-2025
33 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $324 · 2021: $782 · 2022: $1,657 · 2023: $1,131 · 2024: $1,335 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.18 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,719.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $585.81 | 2019-2024 | Libtayo, Dupixent |
| Pfizer INC. | $545.84 | 2019-2025 | |
| Lilly USA, LLC | $461.96 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $435.07 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $320.73 | 2019-2025 | Cabtreo, Jublia |
| Janssen Biotech, INC. | $320.34 | 2019-2025 | Tremfya |
| Ucb, INC. | $294.93 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $279.64 | 2023-2025 | Zoryve |
| Amgen INC. | $272.31 | 2021-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $244.33 | 2021-2025 | |
| Leo Pharma INC. | $217.44 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $186.15 | 2019-2024 | Ilumya |
| Genzyme Corporation | $142.67 | 2021-2025 | |
| Prugen, INC. Pharmaceuticals | $135.49 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $114.00 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $110.10 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $82.91 | 2019-2023 | |
| Biofrontera INC. | $82.08 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $79.13 | 2019-2024 | Klisyri, Seysara |
| Journey Medical Corporation | $70.59 | 2019-2023 | |
| Astellas Pharma US INC | $68.64 | 2023-2025 | Izervay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.05 | 2022-2024 | Spevigo |
| Hydrofera LLC | $50.78 | 2024 | Hydrofera Blue |
| E.R. Squibb & Sons, L.L.C. | $37.70 | 2024-2025 | Sotyktu |
| Sandoz INC. | $24.50 | 2025 | Hyrimoz |
| Dermira, INC. | $18.78 | 2020 | |
| Melinta Therapeutics, LLC | $18.42 | 2019 | |
| Merck Sharp & Dohme LLC | $17.61 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.73 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $12.69 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $12.44 | 2019 | |
| Epi Health, LLC | $9.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.